{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:32:28Z","timestamp":1772559148926,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-17914-1","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T11:01:27Z","timestamp":1756724487000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The administration of passive and active immunotherapy against Syntenin-1 decreased the tumoral growth and pulmonary metastasis in a murine model of triple-negative breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Mar\u00eda Lilia","family":"Nicol\u00e1s-Morales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor Manuel","family":"Luna-Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Alberto","family":"Serrano-Bello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel David","family":"Guerrero-Macedonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia","family":"Rodr\u00edguez-Nava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isela","family":"Parra-Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Espinoza-Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia","family":"Flores-Alfaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luz","family":"del Carmen Alarc\u00f3n-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amalia","family":"Vences-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Cort\u00e9s-Sarabia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"issue":"3","key":"17914_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74(3), 229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"17914_CR2","doi-asserted-by":"publisher","first-page":"4287","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz, S. et al. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an. Cancers (Basel). 13(17), 4287. https:\/\/doi.org\/10.3390\/cancers13174287 (2021).","journal-title":"Cancers (Basel)."},{"key":"17914_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L. et al. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5 (2020).","journal-title":"Breast Cancer Res."},{"issue":"1","key":"17914_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","volume":"41","author":"K Asleh","year":"2022","unstructured":"Asleh, K., Riaz, N. & Nielsen, T. O. Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. J. Exp. Clin. Cancer Res. 41(1), 265. https:\/\/doi.org\/10.1186\/s13046-022-02476-1 (2022).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"17914_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan, F. & Reis-Filho, J. S. Pathogenesis of triple-negative breast cancer. Annu. Rev. Pathol. 17, 181\u2013204. https:\/\/doi.org\/10.1146\/annurev-pathol-042420-093238 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"17914_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.690336","volume":"11","author":"M Zhu","year":"2021","unstructured":"Zhu, M., Liang, C., Zhang, F., Zhu, L. & Chen, D. A Nomogram to predict disease-free survival following neoadjuvant chemotherapy for triple negative breast cancer. Front. Oncol. 11, 690336. https:\/\/doi.org\/10.3389\/fonc.2021.690336 (2021).","journal-title":"Front. Oncol."},{"issue":"3","key":"17914_CR7","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.3390\/ijms24032969","volume":"24","author":"NS Van den Ende","year":"2023","unstructured":"Van den Ende, N. S. Triple-negative breast cancer and predictive markers of response to neoadjuvant chemotherapy: A systematic review. Int. J. Mol. Sci. 24(3), 2969. https:\/\/doi.org\/10.3390\/ijms24032969 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"17914_CR8","doi-asserted-by":"publisher","first-page":"0553","DOI":"10.34133\/research.0553","volume":"7","author":"K Ganesan","year":"2024","unstructured":"Ganesan, K. et al. Ononin inhibits tumor bone metastasis and osteoclastogenesis by targeting mitogen-activated protein kinase pathway in breast cancer. Res. (Wash D C) 7, 0553. https:\/\/doi.org\/10.34133\/research.0553 (2024).","journal-title":"Res. (Wash D C)"},{"key":"17914_CR9","doi-asserted-by":"publisher","first-page":"217734","DOI":"10.1016\/j.canlet.2025.217734","volume":"624","author":"Y Xie","year":"2025","unstructured":"Xie, Y. et al. Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer. Cancer Lett. 624, 217734. https:\/\/doi.org\/10.1016\/j.canlet.2025.217734 (2025).","journal-title":"Cancer Lett."},{"issue":"9","key":"17914_CR10","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.3390\/cancers14092136","volume":"14","author":"E Agostinetto","year":"2022","unstructured":"Agostinetto, E. et al. Immunotherapy for HER2-positive breast cancer: Clinical evidence and future perspectives. Cancers 14(9), 2136. https:\/\/doi.org\/10.3390\/cancers14092136 (2022).","journal-title":"Cancers"},{"key":"17914_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.600573","volume":"10","author":"R Thomas","year":"2021","unstructured":"Thomas, R., Al-Khadairi, G. & Decock, J. Immune checkpoint inhibitors in triple negative breast cancer treatment: Promising future prospects. Front. Oncol. 10, 600573. https:\/\/doi.org\/10.3389\/fonc.2020.600573 (2021).","journal-title":"Front. Oncol."},{"key":"17914_CR12","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1007\/s11864-023-01069-0","volume":"6","author":"V Geurts","year":"2023","unstructured":"Geurts, V. & Kok, M. Immunotherapy for metastatic triple negative breast cancer: Current paradigm and future approaches. Curr. Treat. Options. Oncol. 6, 628\u2013643. https:\/\/doi.org\/10.1007\/s11864-023-01069-0 (2023).","journal-title":"Curr. Treat. Options. Oncol."},{"issue":"23","key":"17914_CR13","doi-asserted-by":"publisher","first-page":"14937","DOI":"10.3390\/ijms232314937","volume":"23","author":"E Kudelova","year":"2022","unstructured":"Kudelova, E. et al. Genetic heterogeneity, tumor microenvironment and immunotherapy in triple-negative breast cancer. Int. J. Mol. Sci. 23(23), 14937. https:\/\/doi.org\/10.3390\/ijms232314937 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"17914_CR14","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/ijms21020515","volume":"21","author":"RC Abbott","year":"2020","unstructured":"Abbott, R. C., Cross, R. S. & Jenkins, M. R. Finding the keys to the CAR: Identifying novel target antigens for T cell redirection immunotherapies. Int. J. Mol. Sci. 21, 515. https:\/\/doi.org\/10.3390\/ijms21020515 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"17914_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41571-020-0387-x","volume":"17","author":"SP Haen","year":"2020","unstructured":"Haen, S. P., L\u00f6ffler, M. W., Rammensee, H.-G. & Brossart, P. Towards new horizons: Characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595\u2013610. https:\/\/doi.org\/10.1038\/s41571-020-0387-x (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"17914_CR16","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.3390\/ijms20174171","volume":"20","author":"T Shimada","year":"2019","unstructured":"Shimada, T., Yasuda, S., Sugiura, H. & Yamagata, K. Syntenin: PDZ protein regulating signaling pathways and cellular functions. Int. J. Mol. Sci. 20, 4171. https:\/\/doi.org\/10.3390\/ijms20174171 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"17914_CR17","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1038\/s41598-021-81697-4","volume":"11","author":"R Kashyap","year":"2021","unstructured":"Kashyap, R. et al. Syntenin-knock out reduces exosome turnover and viral transduction. Sci. Rep. 11, 4083. https:\/\/doi.org\/10.1038\/s41598-021-81697-4 (2021).","journal-title":"Sci. Rep."},{"key":"17914_CR18","doi-asserted-by":"publisher","first-page":"R50","DOI":"10.1186\/bcr3442","volume":"15","author":"Y Yang","year":"2013","unstructured":"Yang, Y. et al. Elevated expression of syntenin in breast cancer is correlated with lymph node metastasis and poor patient survival. Breast Cancer Res. BCR 15, R50. https:\/\/doi.org\/10.1186\/bcr3442 (2013).","journal-title":"Breast Cancer Res. BCR"},{"key":"17914_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103180118","volume":"118","author":"AK Pradhan","year":"2021","unstructured":"Pradhan, A. K. et al. Pharmacological inhibition of MDA-9\/Syntenin blocks breast cancer metastasis through suppression of IL-1\u03b2. Proc. Natl. Acad. Sci. 118, e2103180118. https:\/\/doi.org\/10.1073\/pnas.2103180118 (2021).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"17914_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005848","volume":"11","author":"ED Routh","year":"2023","unstructured":"Routh, E. D. et al. Evaluation of tumor antigen-specific antibody responses in patients with metastatic triple negative breast cancer treated with cyclophosphamide and pembrolizumab. J. Immunother Cancer 11(3), e005848. https:\/\/doi.org\/10.1136\/jitc-2022-005848 (2023).","journal-title":"J. Immunother Cancer"},{"key":"17914_CR21","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12967-020-02421-w","volume":"18","author":"JA Kyte","year":"2020","unstructured":"Kyte, J. A. et al. ICON: A randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. J. Transl. Med. 18, 269. https:\/\/doi.org\/10.1186\/s12967-020-02421-w (2020).","journal-title":"J. Transl. Med."},{"key":"17914_CR22","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1016\/j.cell.2019.03.005","volume":"177","author":"J Wagner","year":"2019","unstructured":"Wagner, J. et al. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell 177, 1330-1345.e18. https:\/\/doi.org\/10.1016\/j.cell.2019.03.005 (2019).","journal-title":"Cell"},{"issue":"1","key":"17914_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.31557\/APJCP.2025.26.1.327","volume":"26","author":"S Gupta","year":"2025","unstructured":"Gupta, S. et al. Screening of oncogenic proteins and development of a multiepitope peptide vaccine targeting AKT1 and PARP1 for breast cancer by integrating reverse vaccinology and immune-informatics approaches. Asian Pac. J. Cancer Prev. 26(1), 327\u2013338. https:\/\/doi.org\/10.31557\/APJCP.2025.26.1.327 (2025).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"17914_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104695","volume":"155","author":"SK Das","year":"2020","unstructured":"Das, S. K. et al. MDA-9\/Syntenin (SDCBP): Novel gene and therapeutic target for cancer metastasis. Pharmacol. Res. 155, 104695. https:\/\/doi.org\/10.1016\/j.phrs.2020.104695 (2020).","journal-title":"Pharmacol. Res."},{"key":"17914_CR25","doi-asserted-by":"publisher","first-page":"12495","DOI":"10.1073\/pnas.1713433114","volume":"114","author":"NS Imjeti","year":"2019","unstructured":"Imjeti, N. S. et al. Syntenin mediates SRC function in exosomal cell-to-cell communication. Proc. Natl. Acad. Sci. 114, 12495\u201312500. https:\/\/doi.org\/10.1073\/pnas.1713433114 (2019).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"17914_CR26","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1038\/sj.onc.1205514","volume":"21","author":"TH Koo","year":"2002","unstructured":"Koo, T. H. et al. Syntenin is overexpressed and promotes cell migration in metastatic human breast and gastric cancer cell lines. Oncogene 21, 4080\u20134088. https:\/\/doi.org\/10.1038\/sj.onc.1205514 (2002).","journal-title":"Oncogene"},{"key":"17914_CR27","doi-asserted-by":"publisher","first-page":"1800143","DOI":"10.1002\/adtp.201800143","volume":"2","author":"NR Christensen","year":"2019","unstructured":"Christensen, N. R. et al. PDZ domains as drug targets. Adv. Ther. 2, 1800143. https:\/\/doi.org\/10.1002\/adtp.201800143 (2019).","journal-title":"Adv. Ther."},{"issue":"12","key":"17914_CR28","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.3390\/pharmaceutics15122791","volume":"15","author":"C Zannella","year":"2023","unstructured":"Zannella, C. et al. SARS-CoV-2 fusion peptide conjugated to a tetravalent dendrimer selectively inhibits viral infection. Pharmaceutics 15(12), 2791. https:\/\/doi.org\/10.3390\/pharmaceutics15122791 (2023).","journal-title":"Pharmaceutics"},{"key":"17914_CR29","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1538\/expanim.19-0148","volume":"69","author":"J Li","year":"2020","unstructured":"Li, J., Wu, H., Liu, Y. & Yang, L. High fat diet induced obesity model using four strains of mice: Kunming, C57BL\/6 BALB\/c and ICR. Exp. Anim. 69, 326\u2013335. https:\/\/doi.org\/10.1538\/expanim.19-0148 (2020).","journal-title":"Exp. Anim."},{"issue":"2","key":"17914_CR30","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1177\/0148607114558489","volume":"40","author":"RA Busch","year":"2016","unstructured":"Busch, R. A., Jonker, M. A., Pierre, J. F., Heneghan, A. F. & Kudsk, K. A. Innate mucosal immune system response of BALB\/c vs C57BL\/6 mice to injury in the setting of enteral and parenteral feeding. JPEN J. Parenter. Enteral. Nutr. 40(2), 256\u2013263. https:\/\/doi.org\/10.1177\/0148607114558489 (2016).","journal-title":"JPEN J. Parenter. Enteral. Nutr."},{"issue":"9","key":"17914_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004709","volume":"10","author":"MM Melssen","year":"2022","unstructured":"Melssen, M. M., Fisher, C. T., Slingluff, C. L. & Melief, C. J. M. Peptide emulsions in incomplete Freund\u2019s adjuvant create effective nurseries promoting egress of systemic CD4+ and CD8+ T cells for immunotherapy of cancer. J. Immunother Cancer 10(9), e004709. https:\/\/doi.org\/10.1136\/jitc-2022-004709 (2022).","journal-title":"J. Immunother Cancer"},{"key":"17914_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000544","author":"KE Pollack","year":"2020","unstructured":"Pollack, K. E. et al. Incomplete Freund\u2019s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment. J. Immunother. Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-000544 (2020).","journal-title":"J. Immunother. Cancer."},{"key":"17914_CR33","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1039\/C9SC04722K","volume":"11","author":"F Samsudin","year":"2020","unstructured":"Samsudin, F., Yi Yeo, J., Ken-En Gan, S. & Bond, J. Not all therapeutic antibody isotypes are equal: the case of IgM versus IgG in Pertuzumab and Trastuzumab. Chem. Sci. 11, 2843\u20132854. https:\/\/doi.org\/10.1039\/C9SC04722K (2020).","journal-title":"Chem. Sci."},{"issue":"1","key":"17914_CR34","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jchromb.2006.09.030","volume":"848","author":"S Hober","year":"2007","unstructured":"Hober, S., Nord, K. & Linhult, M. Protein A chromatography for antibody purification. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 848(1), 40\u201347. https:\/\/doi.org\/10.1016\/j.jchromb.2006.09.030 (2007).","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"17914_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2020.113909","volume":"609","author":"Z Mahshid","year":"2020","unstructured":"Mahshid, Z., Ilnaz, S. M., Mohsen, F. & Alireza, G. Mechanism of antibodies purification by protein A. Anal. Biochem. 609, 113909. https:\/\/doi.org\/10.1016\/j.ab.2020.113909 (2020).","journal-title":"Anal. Biochem."},{"issue":"3","key":"17914_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5455\/javar.2019.f356","volume":"6","author":"LD Assaat","year":"2019","unstructured":"Assaat, L. D. et al. Production of a polyclonal antibody against acrylamide for immunochromatographic detection of acrylamide using strip tests. J. Adv. Vet. Anim. Res. 6(3), 366\u2013375. https:\/\/doi.org\/10.5455\/javar.2019.f356 (2019).","journal-title":"J. Adv. Vet. Anim. Res."},{"key":"17914_CR37","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1038\/s41598-021-81366-6","volume":"11","author":"Y Imura","year":"2021","unstructured":"Imura, Y. et al. El lavado con soluciones alcalinas en la purificaci\u00f3n de la prote\u00edna A mejora las propiedades fisicoqu\u00edmicas de los anticuerpos monoclonales. Sci. Rep. 11, 1827. https:\/\/doi.org\/10.1038\/s41598-021-81366-6 (2021).","journal-title":"Sci. Rep."},{"issue":"9","key":"17914_CR38","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/jssc.201800963","volume":"42","author":"AM Ramos","year":"2019","unstructured":"Ramos, A. M., Gonz\u00e1lez, J. & Aguilar, O. Protein A chromatography: Challenges and progress in the purification of monoclonal antibodies. J. Sep. Sci. 42(9), 1816\u20131827. https:\/\/doi.org\/10.1002\/jssc.201800963 (2019).","journal-title":"J. Sep. Sci."},{"issue":"9","key":"17914_CR39","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.1158\/0008-5472.CAN-07-6210","volume":"68","author":"D Sarkar","year":"2008","unstructured":"Sarkar, D., Boukerche, H., Su, Z. Z. & Fisher, P. B. mda-9\/Syntenin: More than just a simple adapter protein when it comes to cancer metastasis. Cancer Res. 68(9), 3087\u20133093. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6210 (2008).","journal-title":"Cancer Res."},{"key":"17914_CR40","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.1038\/ncomms7842","volume":"6","author":"H Sugiura","year":"2015","unstructured":"Sugiura, H. et al. Rheb activation disrupts spine synapse formation through accumulation of syntenin in tuberous sclerosis complex. Nat. Commun. 6, 6842. https:\/\/doi.org\/10.1038\/ncomms7842 (2015).","journal-title":"Nat. Commun."},{"key":"17914_CR41","doi-asserted-by":"publisher","first-page":"17868","DOI":"10.1038\/s41598-018-36192-8","volume":"8","author":"YJ Chen","year":"2018","unstructured":"Chen, Y. J. et al. Development of a highly sensitive enzyme-linked immunosorbent assay (ELISA) through use of poly-protein G-expressing cell-based microplates. Sci. Rep. 8, 17868. https:\/\/doi.org\/10.1038\/s41598-018-36192-8 (2018).","journal-title":"Sci. Rep."},{"key":"17914_CR42","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/978-1-4939-9077-1_4","volume":"47\u201354","author":"E Moln\u00e1r","year":"1941","unstructured":"Moln\u00e1r, E. Cell-based enzyme-linked immunosorbent assay (Cell-ELISA) analysis of native and recombinant glutamate receptors. Methods Mol. Biol. 47\u201354, 2019. https:\/\/doi.org\/10.1007\/978-1-4939-9077-1_4 (1941).","journal-title":"Methods Mol. Biol."},{"key":"17914_CR43","doi-asserted-by":"publisher","first-page":"5131","DOI":"10.2147\/CMAR.S244748","volume":"12","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Anticancer effects of ACT001 via NF-\u03baB suppression in murine triple-negative breast cancer cell line 4T1. Cancer Manag. Res. 12, 5131\u20135139. https:\/\/doi.org\/10.2147\/CMAR.S244748 (2020).","journal-title":"Cancer Manag. Res."},{"key":"17914_CR44","doi-asserted-by":"publisher","first-page":"54040","DOI":"10.3791\/54040","volume":"114","author":"AV Paschall","year":"2016","unstructured":"Paschall, A. V. & Liu, K. An orthotopic mouse model of spontaneous breast cancer metastasis. J. Vis. Exp. 114, 54040. https:\/\/doi.org\/10.3791\/54040 (2016).","journal-title":"J. Vis. Exp."},{"issue":"7","key":"17914_CR45","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.tcb.2015.02.008","volume":"25","author":"JD Humphries","year":"2015","unstructured":"Humphries, J. D., Paul, N. R., Humphries, M. J. & Morgan, M. R. Emerging properties of adhesion complexes: What are they and what do they do?. Trends Cell Biol. 25(7), 388\u2013397. https:\/\/doi.org\/10.1016\/j.tcb.2015.02.008 (2015).","journal-title":"Trends Cell Biol."},{"issue":"3","key":"17914_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.devcel.2005.07.011","volume":"9","author":"P Zimmermann","year":"2005","unstructured":"Zimmermann, P. et al. Syndecan recycling [corrected] is controlled by syntenin-PIP2 interaction and Arf6. Dev. Cell. 9(3), 377\u2013388. https:\/\/doi.org\/10.1016\/j.devcel.2005.07.011 (2005).","journal-title":"Dev. Cell."},{"issue":"3","key":"17914_CR47","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10555-020-09886-7","volume":"39","author":"AK Pradhan","year":"2020","unstructured":"Pradhan, A. K. et al. MDA-9\/Syntenin\/SDCBP: New insights into a unique multifunctional scaffold protein. Cancer Metastasis Rev. 39(3), 769\u2013781. https:\/\/doi.org\/10.1007\/s10555-020-09886-7 (2020).","journal-title":"Cancer Metastasis Rev."},{"issue":"10","key":"17914_CR48","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/icb.2016.65","volume":"94","author":"AM Collins","year":"2016","unstructured":"Collins, A. M. IgG subclass co-expression brings harmony to the quartet model of murine IgG function. Immunol. Cell Biol. 94(10), 949\u2013954. https:\/\/doi.org\/10.1038\/icb.2016.65 (2016).","journal-title":"Immunol. Cell Biol."},{"issue":"1","key":"17914_CR49","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.immuni.2005.05.010","volume":"23","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn, F., Bruhns, P., Horiuchi, K. & Ravetch, J. V. Fcgamma RIV: A novel FcR with distinct IgG subclass specificity. Immunity 23(1), 41\u201351. https:\/\/doi.org\/10.1016\/j.immuni.2005.05.010 (2005).","journal-title":"Immunity"},{"issue":"45","key":"17914_CR50","doi-asserted-by":"publisher","first-page":"19396","DOI":"10.1073\/pnas.1014515107","volume":"107","author":"F Nimmerjahn","year":"2010","unstructured":"Nimmerjahn, F. et al. Fc\u03b3RIV deletion reveals its central role for IgG2a and IgG2b activity in vivo. Proc. Natl. Acad. Sci. 107(45), 19396\u201319401. https:\/\/doi.org\/10.1073\/pnas.1014515107 (2010).","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17914-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17914-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:10:43Z","timestamp":1757142643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-17914-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["17914"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-17914-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project has the approval of the Internal Committee for the Care and Use of Laboratory Animals (CICUAL) of the Universidad Aut\u00f3noma de Guerrero (CICUAL-02\/2021). All the used Balb\/c mice were obtained from the bioterium of the Universidad Aut\u00f3noma de Guerrero (polyclonal antibody production) and the Hospital Infantil de M\u00e9xico Federico G\u00f3mez (triple negative breast cancer murine model). For animal treatment, we consider the ARRIVE guidelines (). Also, all procedures involving animal manipulation were performed in accordance with NOM-062-ZOO-1999.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All listed authors approved the submitted version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"32134"}}